{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:31:56Z","timestamp":1790775116099,"version":"4.1.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82205086"],"award-info":[{"award-number":["82205086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81904154"],"award-info":[{"award-number":["81904154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of NAFLD is increasing. Preclinical evidences indicate that modulation of the gut microbiome could be a promising target in nonalcoholic fatty liver disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A systematic review and network meta-analysis was conducted to compare the effect of probiotics, synbiotics, prebiotics, fecal microbiota transplant, and antibiotics on the liver-enzyme, metabolic effects and liver-specific in patients with NAFLD. The randomized controlled trails (RCTs), limited to English language were searched from database such as Pubmed, Embase, Web of science and Cochrane Library from inception to November 2024. Review Manager 5.3 was used to to draw a Cochrane bias risk. Inconsistency test and publication-bias were assessed by Stata 14.0. Random effect model was used to assemble direct and indirect evidences. The effects of the intervention were presented as mean differences with 95% confidence interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1921 patients from 37 RCTs were eventually included in our study. 23 RCTs evaluated probiotics, 10 RCTs evaluated synbiotics, 4 RCTs evaluated prebiotics, 3 RCTs evaluated FMT and one RCT evaluated antibiotics. Probiotics and synbiotics were associated with a significantly reduction in alanine aminotransferase [ALT, (MD: \u22125.09; 95%CI: \u22129.79, \u22120.39), (MD: \u22127.38, 95CI%: \u221211.94, \u22122.82)] and liver stiffness measurement by elastograph [LSM, (MD: \u22120.37;95%CI: \u22120.49, \u22120.25), (MD: \u22121.00;95%CI: \u22121.59, \u22120.41)]. In addition to, synbiotics was superior to probiotics in reducing LSM. Synbiotics was associated with a significant reduction of Controlled Attenuation Parameter [CAP, (MD: \u221239.34; 95%CI: \u221274.73, \u22123.95)]. Both probiotics and synbiotics were associated with a significant reduction of aspartate transaminase [AST, (MD: \u22127.81; 95%CI: \u221215.49, \u22120.12), (MD: \u221213.32; 95%CI: \u221223, \u22123.64)]. Probiotics and Allogenic FMT was associated with a significant reduction of Homeostatic Model Assessment for Insulin Resistance [HOMA-IR, (MD: \u22120.7, 95%CI: \u22121.26, \u22120.15), (MD: \u22121.8, 95%CI: \u22123.53, \u2212 0.07)]. Probiotics was associated with a significant reduction of body mass index [BMI, MD: \u22121.84, 95%CI: \u22123.35, \u22120.33].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The supplement of synbiotics and probiotics maybe a promising way to improve liver-enzyme, LSM, and steatosis in patients with NAFLD. More randomized controlled trials are needed to determine the efficacy of FMT and antibiotics on NAFLD. And the incidence of adverse events of MTTs should be further explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , CRD42023450093.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2024.1470185","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:17:45Z","timestamp":1736122665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"11","author":[{"given":"Yijia","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1017\/S0007114517000204","article-title":"Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial","volume":"117","author":"Mofidi","year":"2017","journal-title":"British J Nut"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017\u2014part 1: definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and Management of Nonalcoholic Fatty Liver Disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1586\/17474124.2016.1099433","article-title":"Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis","volume":"10","author":"Golabi","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.chom.2020.07.007","article-title":"Microbiota and fatty liver disease\u2014the known, the unknown, and the future","volume":"28","author":"Lang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"113290","DOI":"10.1016\/j.biopha.2022.113290","article-title":"Diet-gut microbiota-epigenetics in metabolic diseases: from mechanisms to therapeutics","volume":"153","author":"Li","year":"2022","journal-title":"Biomed Exp"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/mnfr.201700252","article-title":"Dual function ofLactobacillus kefiriDH5 in preventing high\u2010fat\u2010diet\u2010induced obesity: direct reduction of cholesterol and upregulation of PPAR\u2010\u03b1 in adipose tissue","volume":"61","author":"Kim","year":"2017","journal-title":"Mol Nutr Food Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"336","DOI":"10.4093\/dmj.2019.0042","article-title":"Combination of probiotics and Salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice","volume":"44","author":"Wang","year":"2020","journal-title":"Diabetes Metab J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1038\/s41467-022-34671-1","article-title":"Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism","volume":"13","author":"Lei","year":"2022","journal-title":"Nat Commun"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"678360","DOI":"10.3389\/fimmu.2021.678360","article-title":"Prebiotic inulin and sodium butyrate attenuate obesity-induced intestinal barrier dysfunction by induction of antimicrobial peptides","volume":"12","author":"Beisner","year":"2021","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3389\/fmicb.2017.02010","article-title":"Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver","volume":"8","author":"Alves","year":"2017","journal-title":"Front Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"110","author":"Sharpton","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.3390\/ijms23158805","article-title":"The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic Steatohepatitis (NASH): a systematic review","volume":"23","author":"Carpi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of Lactobacillus rhamnosus strain GG in Pediatric obesity-related liver disease","volume":"52","author":"Vajro","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5812\/ircmj.46017","article-title":"The effect of probiotic and\/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: a double blind randomized clinical trial","volume":"19","author":"Javadi","year":"2017","journal-title":"Iran Red Crescent Med J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"15489","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"American Heart Association Council on arteriosclerosis, thrombosis and vascular biology; council on hypertension; council on the kidney in cardiovascular disease; council on lifestyle and cardiometabolic health; and council on peripheral vascular disease. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1055\/a-1930-6658","article-title":"Shared mechanisms between cardiovascular disease and NAFLD","volume":"42","author":"Huang","year":"2022","journal-title":"Semin Liver Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","article-title":"Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives","volume":"55","author":"Hu","year":"2020","journal-title":"J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"111235","DOI":"10.1016\/j.biopha.2021.111235","article-title":"The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD","volume":"135","author":"Huang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1014010","DOI":"10.3389\/fnut.2023.1014010","article-title":"Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2023","journal-title":"Front Nutr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/jgh.16256","article-title":"Use of probiotics, prebiotics, and synbiotics in non\u2010alcoholic fatty liver disease: a systematic review and meta\u2010analysis","volume":"38","author":"Rong","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr Rev"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.14218\/JCTH.2022.00415","article-title":"Akkermansia muciniphila and Bifidobacterium bifidum prevent NAFLD by regulating FXR expression and gut microbiota","volume":"11","author":"Nian","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"5978","DOI":"10.3748\/wjg.v12.i37.5978","article-title":"Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells","volume":"12","author":"Helwig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"ref32","first-page":"199","volume-title":"Lactic Acid Bacteria: Genetics, Metabolism and Applications","author":"Siezen","year":"1999"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"14812","DOI":"10.1038\/s41598-023-41596-2","article-title":"Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch","volume":"13","author":"Liao","year":"2023","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"17562848231174299","DOI":"10.1177\/17562848231174299","article-title":"The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis","volume":"16","author":"Cai","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0183-1","article-title":"Sodium butyrate reduces high-fat diet-induced non-alcoholic Steatohepatitis through upregulation of hepatic GLP-1R expression","volume":"50","author":"Zhou","year":"2018","journal-title":"Exp Mol Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/dom.14569","article-title":"Weight loss interventions and nonalcoholic fatty liver disease: optimizing liver outcomes","volume":"24","author":"Finer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/diagnostics10060395","article-title":"Could SCGF-Beta levels be associated with inflammation markers and insulin resistance in male patients suffering from obesity-related NAFLD?","volume":"10","author":"Tarantino","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/biomedicines11020640","article-title":"The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease","volume":"11","author":"Ayob","year":"2023","journal-title":"Biomedicines"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s11739-023-03339-z","article-title":"Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?","volume":"18","author":"Tarantino","year":"2023","journal-title":"Intern Emerg Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jhep.2022.01.010","article-title":"Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK biobank participants","volume":"76","author":"Petermann-Rocha","year":"2022","journal-title":"J Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/ijms17060932","article-title":"Effect of a prebiotic formulation on frailty syndrome: a randomized, double-blind clinical trial","volume":"17","author":"Buigues","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of Fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Ann Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/hep4.1601","article-title":"Donor Fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with Steatohepatitis","volume":"4","author":"Witjes","year":"2020","journal-title":"Hepatol Commun"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3345\/cep.2021.00787","article-title":"Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis: a randomized clinical trial","volume":"65","author":"Rodrigo","year":"2022","journal-title":"Clin Exp Pediatrics"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"93192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP\u00ae BCMC\u00ae strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad","year":"2021","journal-title":"Nutrients"},{"key":"ref49","first-page":"282","article-title":"Effects of synbiotics supplementation in lean patients with nonalcoholic fatty liver disease: study protocol of a pilot randomized double-blind clinical trial","volume":"19","author":"Mofidi","year":"2016","journal-title":"Arch Iran Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non\u2010alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J Dig Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis","volume":"57","author":"Malaguarnera","year":"2012","journal-title":"Dig Dis Sci"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.47203\/IJCH.2019.v31i01.009","article-title":"Probiotic and lifestyle modification in obese pediatrics with non-alcoholic fatty liver disease","volume":"31","author":"Goyal","year":"2019","journal-title":"Indian J Community Health"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/nu8070397","article-title":"Beneficial effect of Synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic Steatohepatitis","volume":"8","author":"Ferolla","year":"2016","journal-title":"Nutrients"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e000315","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"Gastroenterology"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic Fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"A randomised placebo controlled trial of VSL#3(\u00ae) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"E21464","DOI":"10.1097\/MD.0000000000021464","article-title":"Protective effect of probiotics in patients with non-alcoholic fatty liver disease","volume":"99","author":"Cai","year":"2020","journal-title":"Medicine"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur J Nutr"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, c-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"Int J Prev Med"},{"key":"ref63","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects ofVSL#3 in obese children with non\u2010alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci Rep"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clnesp.2020.06.020","article-title":"The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial","volume":"39","author":"Abhari","year":"2020","journal-title":"Clin Nutr ESPEN"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3350\/cmh.2018.0006","article-title":"Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease","volume":"24","author":"Sayari","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"ref68","first-page":"82","volume-title":"The effect of GeriLact on non-alcoholic fatty liver diseaseJ Kerman Univ Med Sci","author":"Sadrkabir","year":"2020"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2019","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"278","DOI":"10.17179\/excli2016-846","article-title":"Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease","volume":"16","author":"Ekhlasi","year":"2017","journal-title":"EXCLI J"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot","volume":"30","author":"Abdel-Razik","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"846873","DOI":"10.3389\/fnut.2022.846873","article-title":"Probiotic therapy with VSL#3\u00ae in patients with NAFLD: a randomized clinical trial","volume":"9","author":"Derosa","year":"2022","journal-title":"Front Nutr"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.tjnut.2023.05.019","article-title":"Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic Steatohepatitis: a randomized controlled trial","volume":"153","author":"Escouto","year":"2023","journal-title":"J Nutr"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3390\/nu16111571","article-title":"Prebiotic treatment in patients with nonalcoholic fatty liver disease (NAFLD)-a randomized pilot trial","volume":"16","author":"Reshef","year":"2024","journal-title":"Nutrients"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12876-024-03424-3","article-title":"The effect of probiotic supplementation on non-alcoholic fatty liver disease (NAFLD) fibrosis score in patients attending a tertiary hospital clinic in Cairo, Egypt","volume":"24","author":"Abd El Hamid","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1470185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:17:50Z","timestamp":1736122670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2024.1470185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":75,"alternative-id":["10.3389\/fnut.2024.1470185"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2024.1470185","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"article-number":"1470185"}}